Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Operating Leases (2020 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed Operating Leases for 2 consecutive years, with $29.7 million as the latest value for Q3 2021.

  • For the quarter ending Q3 2021, Operating Leases rose 241.69% year-over-year to $29.7 million, compared with a TTM value of $29.7 million through Sep 2021, up 241.69%, and an annual FY2020 reading of $7.7 million, changed N/A over the prior year.
  • Operating Leases was $29.7 million for Q3 2021 at Black Diamond Therapeutics, up from $13.4 million in the prior quarter.
  • Across five years, Operating Leases topped out at $29.7 million in Q3 2021 and bottomed at $186000.0 in Q2 2020.